Original Article

Mean Platelet Volume and Platelet Distribution Width Level in Patients with Panic Disorder

Ramdas Sarjerao Ransing, Bharat Patil1, Oimityah Grigo2

Background: Changes in platelet indices have been reported in patients with panic disorder (PD). However, previous study findings are contradictory and inconclusive. The aim of this study was to evaluate and compare the platelet indices in patients with PD.

Materials and Methods: Patients with PD (n = 123) and healthy controls (n = 133) were enrolled in this case control study. The platelet indices (mean platelet volume [MPV] and platelet distribution width [PDW]) along with red blood cell (RBC) indices (RBC count and red cell distribution width [RDW]) were compared between the two groups using the unpaired t-test.

Results: Patients with PD had lower MPV (7.53 ± 0.93 fL vs. 8.91 ± 1.24 fL, P < 0.0001), higher PDW (16.96 ± 0.85 fL vs. 14.71 ± 2.07 fL, P < 0.0001), and higher platelet count (274.2 ± 80.66 × 109 L−1 vs. 243.1 ± 93.89 × 109 L−1, P < 0.005) than the healthy controls. Furthermore, there were significant differences between patients with PD and healthy controls in terms of their RBC count (4.32 ± 0.56 × 1012 L−1 vs. 4.08 ± 0.80 × 1012 L−1, P = 0.007) and RDW (16.48 ± 2.26 fL vs. 15.01 ± 2.25 fL, P < 0.0001).

Conclusion: Patients with PD have increased PDW and RDW. The platelet and RBC indices may prove to be useful etiological and prognostic markers in patients with PD.

Keywords: Mean platelet volume, panic disorder, platelet distribution width, red cell distribution width

INTRODUCTION

Panic disorder (PD) is a common and serious psychiatric illness, characterized by sudden, unexpected, and recurring panic attacks.[1] Panic attack symptoms include palpitations, sweating, shaking, shortness of breath, and fear of losing control.[2] These symptoms resemble those of serious medical conditions such as myocardial infarction and stroke.

Serotonergic system dysfunction and serotonin (5-hydroxytryptamine [5-HT]) have been postulated to play a role in the neurobiology of PD. Furthermore, this hypothesis was supported by clinical and experimental studies, brain imaging, genetic studies, and pharmacotherapy of PD.[3] Two opposing hypotheses, 5-HT excess or over activity[4] and 5-HT deficit or under activity,[5] have been proposed for explaining the panic phenomenon. Excess theory suggested that patients with PD had increased level of 5-HT release or hypersensitivity in postsynaptic 5-HT receptors. Deficit theory suggested that 5-HT had restraining effects on PD, particularly in brain regions such as the dorsal periaqueductal, 5-HT deficit may facilitate panic episodes. The 5-HT system may have a dual role in the modulation of different forms of pathological anxiety; it not only inhibits panic responses but also contributes to anticipatory or generalized anxiety.[6]

5-HT is a neurotransmitter of the central nervous system (CNS), which plays a vital role in platelet aggregation and vascular tone regulation.[7] Platelet and serotonergic neurons use the same serotonin transporter to transport serotonin into their cells and ways to store it. These cells are major storage sites for serotonin.[8] Moreover, previous studies have indicated that serotonin levels in the cerebrospinal fluid and platelets are strongly correlated.[9,10] Platelet indices such as mean platelet volume (MPV) and platelet distribution width (PDW) were extensively studied in patients with depression, schizophrenia, and bipolar disorders for identifying the risk of developing cardiovascular diseases.[11-13] Furthermore, patients with PD are at increased risk of cardiovascular diseases.[14]

Until now, only few studies have been conducted to evaluate the MPV in patients with PD; however, their results were inconclusive and contradictory.[15-17] Furthermore, their findings were also limited because of small sample size, poor inclusion and exclusion criteria, and lack of use of standardized scales. To overcome these limitations, the present study primarily

Address for correspondence: Dr. Ramdas Sarjerao Ransing, Department of Psychiatry, B K L Walawalkar Rural Medical College, Sawarde, Ratnagiri - 415 606, Maharashtra, India. E-mail: ramdas_ransing123@yahoo.co.in

Quick Response Code: 10.4103/jnrp.jnrp_445_16

How to cite this article: Ransing RS, Patil B, Grigo O. Mean platelet volume and platelet distribution width level in patients with panic disorder. J Neurosci Rural Pract 2017;8:174-8.
aimed to compare the MPV values in patients with PD and healthy controls. Furthermore, we aimed to compare the platelet and red blood cell (RBC) indices between patients with PD and healthy controls.

**Materials and Methods**

This case-control study was conducted for 6 months (January 1, 2016 to June 30, 2016) at tertiary care hospital and was approved by the Institutional Ethical Committee.

**Sample size**

For sample size calculation, we predicted the MPV (mean ± standard deviation [SD]) of patients with PD (cases) and controls (8.8 ± 0.9 fl vs. 9.2 ± 0.8 fl) on the basis of previously conducted studies.[15,18] On the basis of the considerations (i.e. power of study, 95%; alpha risk, 5%; and equal number of cases and controls), a sample size of >118 in each group was considered adequate for the present study.

**Patients**

All patients attending emergency services of psychiatry department were evaluated by psychiatrist for the presence of PD. One hundred and twenty-three patients diagnosed as having PD (aged 18–45 years) with or without agoraphobia were included in the study following the criteria of the Diagnostic and Statistical Manual of Mental Disorders-fourth edition-text revision.[2] Patients with comorbid substance abuse, major depression, dysthymia, acute or chronic medical illness, psychotic disorder, diabetes mellitus, and cardiovascular diseases including hypertension, pregnancy, neurological/neurodevelopmental disorder, smoking, and generalized anxiety disorder were excluded from the study. Age- and sex-matched 133 participants from a community with negative history for PD and fulfilling the exclusion criteria of cases (mentioned above) were included in the control group.

**Assessment**

After explaining the aims and purpose of the study, a written informed consent was obtained from each participant. Subsequently, they were assessed for sociodemographic data, MPV, and other hematological parameters. Three milliliters venous blood of each patient/participant was collected under all aseptic precaution in ethylenediaminetetraacetic acid (EDTA)-containing sterile tubes, and the blood samples were shifted to the hematology laboratory of our hospital. The complete blood counts, platelet indices (MPV and PDW), and RBC indices (Red cell distribution width [RDW] and RBC count) were determined within 60 min using an automated hematology analyzer (Beckman coulter, AcT Diff 2/02020) to minimize the potential influence of EDTA on the MPV. Peripheral blood smear examinations were also performed to provide visual confirmation of the automated results. The reference ranges for MPV and PDW were 8.6–15.5 fl and 8.1–25.0 fl, respectively.[19] All the blood samples were analyzed daily to avoid systemic inconsistency at the same laboratory of our tertiary care teaching hospital.

**Data analysis**

Data analysis was conducted using SPSS Version. 21.0 (IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Armonk, NY). The categorical variables (e.g., gender, place of residence) were expressed in percentages and analyzed through independent Chi-square test and Fisher exact test. The quantitative data were expressed as mean ± SD and compared using the independent t-test. For each test, the significance level was set at P < 0.05.

**Results**

Table 1 shows the sociodemographic characteristics of patients with PD and healthy controls. The two groups did not have statistically significant differences in terms of their age, gender, and place of residence. Table 2 demonstrates the clinical characteristics of patients with PD and healthy controls. The MPV of the patients with PD was significantly lower than that of healthy controls (7.53 ± 0.93 fl vs. 8.91 ± 1.24 fl, 0.20±0.06

### Table 1: Sociodemographic characteristic patients with panic disorder and healthy controls

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients with PD (n=123)</th>
<th>Healthy controls (n=133)</th>
<th>Level of significance (P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)a</td>
<td>31.85±11.48</td>
<td>31.28±9.99</td>
<td>t=0.42, df=254, P=0.66</td>
</tr>
<tr>
<td>Sexb (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>52 (39.10)</td>
<td>65 (45.45)</td>
<td>P=0.32</td>
</tr>
<tr>
<td>Female</td>
<td>81 (60.90)</td>
<td>78 (54.55)</td>
<td></td>
</tr>
<tr>
<td>Residenceb (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urban</td>
<td>37 (30.08)</td>
<td>26 (19.55)</td>
<td>P=0.059</td>
</tr>
<tr>
<td>Rural</td>
<td>86 (69.92)</td>
<td>107 (80.45)</td>
<td></td>
</tr>
</tbody>
</table>

aUnpaired t-test, bFisher exact test. SD: Standard deviation, PD: Panic disorder

### Table 2: Clinical characteristic of patients with panic disorder and healthy controls

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients with PD (n=123)</th>
<th>Healthy controls (n=133)</th>
<th>Level of significance (P, df=254)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>11.97±1.83</td>
<td>11.5±2.39</td>
<td>t=1.75, P=0.08</td>
</tr>
<tr>
<td>RBC count (×10^12/L)</td>
<td>4.32±0.56</td>
<td>4.08±0.80</td>
<td>t=2.68, P=0.007</td>
</tr>
<tr>
<td>WBC count (×10^9/L)</td>
<td>8.35±0.27</td>
<td>9.22±4.41</td>
<td>t=1.81, P=0.07</td>
</tr>
<tr>
<td>Platelet count (×10^12/L)</td>
<td>274.2±80.66</td>
<td>243.1±93.89</td>
<td>t=2.82, P=0.005</td>
</tr>
<tr>
<td>MCV (fL)</td>
<td>84.96±10.14</td>
<td>83.08±10.53</td>
<td>t=1.45, P=0.14</td>
</tr>
<tr>
<td>MCH (pg)</td>
<td>27.91±3.91</td>
<td>28.31±4.44</td>
<td>t=0.76, P=0.44</td>
</tr>
<tr>
<td>MCHC (g/L)</td>
<td>32.77±1.35</td>
<td>34.09±1.47</td>
<td>t=7.48, P&lt;0.0001</td>
</tr>
<tr>
<td>RDW (fL)</td>
<td>16.48±2.26</td>
<td>15.01±2.25</td>
<td>t=5.18, P&lt;0.0001</td>
</tr>
<tr>
<td>MPV (fL)</td>
<td>7.53±0.93</td>
<td>8.91±1.24</td>
<td>t=10.04, P&lt;0.0001</td>
</tr>
<tr>
<td>PCT (%)</td>
<td>0.20±0.06</td>
<td>0.2±0.07</td>
<td>t=0.55, P=0.58</td>
</tr>
<tr>
<td>PDW (fL)</td>
<td>16.96±0.85</td>
<td>14.71±2.07</td>
<td>t=11.16, P≤0.0001</td>
</tr>
</tbody>
</table>

However, the mechanism of increased platelet activity and consequently, PDW has not been fully elucidated. Increased PDW may be a marker of increased platelet activity and abnormal function of platelets. This abnormal function of the platelets leads to decreased platelet size and is a more specific marker of platelet activation than MPV.

Comparison between patients with panic disorder and healthy controls in terms of mean platelet volume and platelet distribution width (mean ± standard deviation)

Figure 1: In this study, lower values of MPV may be due to abnormal 5-HT transporter rate and its metabolism; this finding was consistent with those of a previously conducted study. Disordered platelets and decreased platelet activity share a pathophysiology for some mental disorders, and PD may be one of them. Modification in serotonin levels and its activity and abnormalities in 5-HT1A receptor functioning in PD has been reported by many researchers. In addition, this finding provides indirect evidence for the 5-HT deficit hypothesis postulated for PD instead of the 5-HT excess hypothesis.

Platelet reactivity was measured in terms of MPV, PDW, and platelet count. MPV represents the variability in platelet size and is a more specific marker of platelet activation than MPV.

In general, MPV and PDW are inversely related to each other; therefore, patients with statistically low MPV value should have high PDW. In the present study, PDW was higher in patients with PD than in healthy controls. The findings of our study are in accordance with the MPV–PDW relationship and provide more marked clinical relevance. Kokacya et al. did not report the status of PDW, and Gögçegöz Gül et al. reported that the difference was insignificant. A substantial significant increase in MPV without any changes in PDW and platelet count is highly unlikely to occur; therefore, we tentatively believe that abnormal 5-HT metabolism reflects abnormal function of the platelets. This leads to decreased MPV and increased PDW, which are markers and the determinants of platelet functions. This abnormal function of platelets may be due to different variations in genetic composition of the Indian population. Increased PDW is one of the crucial prognostic factors in patients with myocardial infarction and patients with PD are at increased risk of cardiac diseases. Therefore, increased PDW may be a useful predictor for cardiac diseases in patients with PD and may help in early detection of individuals at risk for cardiac diseases.

In the present study, patients with PD had increased RBC count and RDW, which support findings of previously conducted retrospective study. An increased value of RDW in an otherwise normal complete blood count...
mostly represents early iron deficiency, other nutritional deficiencies (Vitamin B12, folic acid, zinc), chronic stress, and cardiovascular diseases.\[^{34,35}\]\[^{34,38‑40}\]\[^{41}\] In addition to RDW, several other factors related to RBCs (i.e., hemoglobin, hematocrit, and erythrocyte sedimentation rates) were identified as peripheral markers of inflammation and chronic stress and were associated with cardiovascular diseases.\[^{36,37}\]\[^{36}\] Although the relationship between RBC count and cardiovascular diseases remains unclear, a strong relationship between RDW and cardiovascular diseases has been demonstrated in several studies.\[^{34,38‑40}\]\[^{41}\] In a previously conducted study, increased RDW and RBC count was reported in patients with depression, which improved after successful treatment with antidepressants.\[^{41}\]

The findings of our study suggest that the governing hematological parameters (RDW, RBC count, MPV, and PDW) may have an etiological role and a prognostic significance in patients with PD, either independently or interdependently. Therefore, further research is warranted to study the combined effect of these parameters rather than that of individual parameters. One remarkable finding of our study was that variability in any of the RBC indices (RDW) or platelet indices (PDW) may be clinically important in identifying the risk of coronary artery diseases and may have a prognostic significance in patients with PD. Furthermore, Current study findings and previous literature suggest that the combination of PDW-RDW may have clinical significance than the MPV-RDW or MPV-PDW in patients with PD.\[^{15‑17}\]

In addition, MCHC was significantly lower in patients with PD than in healthy controls. MCHC is defined as the average hemoglobin level in RBC, and lower MCHC is associated with poorer outcomes in patients with myocardial infarction.\[^{40}\]\[^{40}\] MCHC is an independent prognostic factor and an inflammatory marker similar to RDW.\[^{41}\] The most novel and crucial finding of previous study is that the inflammatory process reduces MCHC,\[^{42}\] which is supports the inflammatory or immunological origin of PD and risk to cardiovascular diseases. In addition, we reported increased RDW and PDW values.\[^{42}\]\[^{43}\]\[^{44}\]\[^{45}\]\[^{46}\]\[^{47}\]\[^{48}\]\[^{49}\]\[^{50}\]\[^{51}\]\[^{52}\]\[^{53}\]\[^{54}\]\[^{55}\]\[^{56}\]\[^{57}\]\[^{58}\]\[^{59}\]\[^{60}\]\[^{61}\]\[^{62}\]\[^{63}\]\[^{64}\]\[^{65}\]\[^{66}\]\[^{67}\]\[^{68}\]\[^{69}\]\[^{70}\]\[^{71}\]\[^{72}\]\[^{73}\]\[^{74}\]\[^{75}\]\[^{76}\]\[^{77}\]\[^{78}\]\[^{79}\]\[^{80}\]\[^{81}\]\[^{82}\]\[^{83}\]\[^{84}\]\[^{85}\]\[^{86}\]\[^{87}\]\[^{88}\]\[^{89}\]\[^{90}\]\[^{91}\]\[^{92}\]\[^{93}\]\[^{94}\]\[^{95}\]\[^{96}\]\[^{97}\]\[^{98}\]\[^{99}\]\[^{100}\]\[^{101}\]\[^{102}\]\[^{103}\]\[^{104}\]\[^{105}\]\[^{106}\]\[^{107}\]\[^{108}\]\[^{109}\]\[^{110}\]\[^{111}\]\[^{112}\]\[^{113}\]\[^{114}\]\[^{115}\]\[^{116}\]\[^{117}\]\[^{118}\]\[^{119}\]\[^{120}\]\[^{121}\]\[^{122}\]\[^{123}\]\[^{124}\]\[^{125}\]\[^{126}\]\[^{127}\]\[^{128}\]\[^{129}\]\[^{130}\]\[^{131}\]\[^{132}\]\[^{133}\]\[^{134}\]\[^{135}\]\[^{136}\]\[^{137}\]\[^{138}\]\[^{139}\]\[^{140}\]\[^{141}\]\[^{142}\]\[^{143}\]\[^{144}\]\[^{145}\]\[^{146}\]\[^{147}\]\[^{148}\]\[^{149}\]\[^{150}\]\[^{151}\]\[^{152}\]\[^{153}\]\[^{154}\]\[^{155}\]\[^{156}\]\[^{157}\]\[^{158}\]\[^{159}\]\[^{160}\]\[^{161}\]\[^{162}\]\[^{163}\]\[^{164}\]\[^{165}\]\[^{166}\]\[^{167}\]\[^{168}\]\[^{169}\]\[^{170}\]\[^{171}\]\[^{172}\]\[^{173}\]\[^{174}\]\[^{175}\]\[^{176}\]\[^{177}\]\[^{178}\]\[^{179}\]\[^{180}\]\[^{181}\]\[^{182}\]\[^{183}\]\[^{184}\]\[^{185}\]\[^{186}\}\]

**Strength and limitations**

The present study was a case-control study with an adequate sample size. All other hematological parameters were also considered while interpreting the results. Though there are few studies which suggest the contradictory evidence of MPV-RDW or MPV-PDW in patients with PD. This study suggests that the elevated RDW and PDW may have better clinical significance rather than MPV. The results of this study certainly lead to strong, albeit, indirect conclusions, which will help clinicians and researchers in elucidating the possible role of serotonergic stress in the genesis of PD. In addition, the levels of inflammatory markers such as interleukin (IL)-6, IL-3, thyroid peroxidase, which were positively associated with platelet indices were not measured. Prospective, comprehensive, multicentric, and large-scale studies are warranted to explore the role of these indices in patients with PD and any possible link with cardiovascular diseases.

**CONCLUSION**

The MPV decreased in patients with PD, whereas the PDW, RDW, and RBC count increased; these findings were in accordance with the inflammatory origin of PD. The individual platelet indices may have little clinical significance; however, a combination of RBC and platelet indices more likely to have an etiological role and a prognostic significance in patients with PD. These factors may provide a link between PD and cardiace diseases.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**


